DPP-4 inhibitor-based drugs used to treat diabetes continue to decline this year. Sales of prescriptions for major products such as Janumet, Trajenta, and Galvus fell one after another. LG Chem's Zemimet, which rose to No. 1 in the market last year, is the only top-tier item to grow, recording 23 billion won in quarterly prescriptions.

According to UBIST, a pharmaceutical market research firm on the 29th, the market for diabetes treatments affiliated with DPP-4 inhibitors in the first quarter was estimated at 151.2 billion won. It decreased 2.2% from 154.6 billion won a year earlier.

The top six products, which record more than 10 billion won in quarterly prescriptions, saw their prescrip